Tech Company Financing Transactions

Visterra Funding Round

Visterra, operating out of Waltham, raised $8.1 million in investment from Bill & Melinda Gates Foundation and Omega Funds.

Transaction Overview

Company Name
Announced On
12/2/2013
Transaction Type
Venture Equity
Amount
$8,100,000
Round
Series A
Proceeds Purpose
Proceeds will be used to further develop and validate Visterra's technology platform and advance its proprietary infectious disease product pipeline. The company's lead product candidate, VIS410, is a broad spectrum antibody for the prevention and treatment of both seasonal and pandemic influenza.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 2nd Ave.
Waltham, MA 02451
USA
Email Address
Overview
Visterra, Inc. is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. The Company focuses on technologies that can interrogate how pathogens interact with human cells, a critical first step in the disease process.
Profile
Visterra LinkedIn Company Profile
Social Media
Visterra Company Twitter Account
Company News
Visterra News
Facebook
Visterra on Facebook
YouTube
Visterra on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Brian Pereira
  Brian Pereira LinkedIn Profile  Brian Pereira Twitter Account  Brian Pereira News  Brian Pereira on Facebook
Chief Scientific Officer
Zachary Shriver
  Zachary Shriver LinkedIn Profile  Zachary Shriver Twitter Account  Zachary Shriver News  Zachary Shriver on Facebook
Vice President
Jean Bender
  Jean Bender LinkedIn Profile  Jean Bender Twitter Account  Jean Bender News  Jean Bender on Facebook
VP - Administration
Chris Kiefer
  Chris Kiefer LinkedIn Profile  Chris Kiefer Twitter Account  Chris Kiefer News  Chris Kiefer on Facebook
VP - Bus. Development
Greg Miller
  Greg  Miller LinkedIn Profile  Greg  Miller Twitter Account  Greg  Miller News  Greg  Miller on Facebook
VP - Finance
Todd Curtis
  Todd Curtis LinkedIn Profile  Todd Curtis Twitter Account  Todd Curtis News  Todd Curtis on Facebook
VP - R & D
Greg Babcock
  Greg Babcock LinkedIn Profile  Greg Babcock Twitter Account  Greg Babcock News  Greg Babcock on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/2/2013: Biodesix venture capital transaction
Next: 12/2/2013: Xagenic venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary